The stock of Elanco Animal Health Inc (ELAN) has seen a -3.33% decrease in the past week, with a 5.78% gain in the past month, and a 26.78% flourish in the past quarter. The volatility ratio for the week is 1.64%, and the volatility levels for the past 30 days are at 1.78% for ELAN. The simple moving average for the past 20 days is -1.86% for ELAN’s stock, with a 9.15% simple moving average for the past 200 days.
Is It Worth Investing in Elanco Animal Health Inc (NYSE: ELAN) Right Now?
Elanco Animal Health Inc (NYSE: ELAN) has a price-to-earnings ratio that is above its average at 17.82x. The stock has a 36-month beta value of 1.68. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for ELAN is 491.95M, and at present, short sellers hold a 5.32% of that float. On June 24, 2025, the average trading volume of ELAN was 6.10M shares.
ELAN) stock’s latest price update
The stock of Elanco Animal Health Inc (NYSE: ELAN) has increased by 3755650 when compared to last closing price of 13.46.Despite this, the company has seen a loss of -3.33% in its stock price over the last five trading days. prnewswire.com reported 2025-06-12 that Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind., June 12, 2025 /PRNewswire/ — Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP), paving the way for the product’s marketing authorization in the European Union in the next 60 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with UBS repeating the rating for ELAN by listing it as a “Buy.” The predicted price for ELAN in the upcoming period, according to UBS is $18 based on the research report published on December 09, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $14. The rating they have provided for ELAN stocks is “Market Perform” according to the report published on December 02nd, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to ELAN, setting the target price at $15 in the report published on September 19th of the previous year.
ELAN Trading at 13.55% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.03% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELAN starting from Kurzius Lawrence Erik, who purchase 10,000 shares at the price of $10.90 back on Mar 07 ’25. After this action, Kurzius Lawrence Erik now owns 101,459 shares of Elanco Animal Health Inc, valued at $109,000 using the latest closing price.
Kurzius Lawrence Erik, the Director of Elanco Animal Health Inc, purchase 10,000 shares at $10.20 during a trade that took place back on Mar 11 ’25, which means that Kurzius Lawrence Erik is holding 111,459 shares at $102,000 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.46 for the gross margin
The net margin for Elanco Animal Health Inc stands at 0.08. The total capital return value is set at 0.02. Equity return is now at value 6.01, with 2.77 for asset returns.
Based on Elanco Animal Health Inc (ELAN), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.69. The interest coverage ratio of the stock is 1.14.
Currently, EBITDA for the company is 1.49 billion with net debt to EBITDA at 6.24. When we switch over and look at the enterprise to sales, we see a ratio of 2.38. The receivables turnover for the company is 4.18for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.71.
Conclusion
To sum up, Elanco Animal Health Inc (ELAN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
